Search

Your search keyword '"Friberg, Lena E."' showing total 39 results

Search Constraints

Start Over You searched for: Author "Friberg, Lena E." Remove constraint Author: "Friberg, Lena E." Publisher american association for cancer research (aacr) Remove constraint Publisher: american association for cancer research (aacr)
39 results on '"Friberg, Lena E."'

Search Results

3. CCR Translation for This Article from A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

7. CCR Translation for This Article from A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

8. Supplementary Table from Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

9. Supplementary Figure from Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

10. Supplementary Figure from Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

11. Supplementary Table from Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

12. Supplementary Table 1 from CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity

14. Supplementary Table 1 from CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity

16. Supplementary Figure 1 from CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity

17. Supplementary Figure from Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

18. Supplementary Methods, Figures 1 - 4, Tables 1 - 3 from Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel

20. Supplementary Figure 1 from CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity

21. Supplementary Table 1 from A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

22. Supplementary Methods, Figures 1 - 4, Tables 1 - 3 from Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel

23. Supplementary Table 1 from A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

25. Supplementary Figure 1 from A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

26. Supplementary Figure 1 from A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

27. Supplementary Figure from Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

30. Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

33. A Pharmacogenetic Predictive Model for Paclitaxel Clearance Based on the DMET Platform

34. CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity

35. A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

37. Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel

Catalog

Books, media, physical & digital resources